FindTrial
Sign In

[18F]PI-2620

DRUG12 trials

Sponsors

AC Immune S.A., University Clinic Of Navarra, Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau, Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer, Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Conditions

Alzheimer DiseaseAlzheimer Disease (AD)Alzheimer diseaseAlzheimer's diseaseAlzheimer´s Disease.Cognitively NormalDown SyndromeDown Syndrome.

Early Phase 1

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
CompletedNCT03510572
Asan Medical CenterAlzheimer Disease, Frontotemporal Dementia, Healthy Volunteer +1
Start: 2018-06-04End: 2019-07-31Updated: 2020-12-14

Phase 1

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
CompletedNCT04566003
Genentech, Inc.Alzheimer Disease (AD)
Start: 2020-10-26End: 2023-06-27Updated: 2023-07-12
Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury
TerminatedNCT05337774
Life Molecular Imaging SAMild Traumatic Brain Injury
Start: 2021-06-07End: 2022-04-30Updated: 2024-05-14
A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer’s disease and in adults with Down syndrome (ABATE)
RecruitingCTIS2022-500069-29-00
AC Immune S.A.Alzheimer's disease
Start: 2022-11-02Target: 30Updated: 2025-08-04

Phase 2

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
CompletedNCT03903211
Jae Seung KimAlzheimer Disease, Cognitively Normal, Mild Cognitive Impairment
Start: 2019-04-09End: 2021-02-28Updated: 2023-09-06
ASSESSMENT OF THE BRAIN DEPOSIT OF TAU 4R DETECTED BY BRAIN PET WITH 18F-PI2620 IN PROGRESSIVE SUPRANUCLEAR PALSY COMPARED TO CONTROLS WITHOUT NEURODEGENERATIVE TAUOPATHY 4R: A CLINICAL TRIAL
Active, not recruitingCTIS2023-503538-37-00
University Clinic Of NavarraProgressive supranuclear palsy
Start: 2023-11-13Target: 51Updated: 2023-08-07
Sleep and Temperature Disturbance as risk factors for Alzheimer's Disease in Down Syndrome: a Longitudinal Study.
RecruitingCTIS2023-506609-21-00
Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant PauAlzheimer´s Disease., Down Syndrome.
Start: 2024-04-09Target: 60Updated: 2025-04-22
Quantification tools for a novel tau PET marker in a rare neurological disease: 18F-PI-2620 in progressive supranuclear palsy
RecruitingCTIS2023-508718-40-00
Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I SunyerParkinson's disease, Progressive supranuclear palsy
Start: 2025-01-09Target: 66Updated: 2024-03-05
Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study)
RecruitingCTIS2023-510508-31-01
Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Paucognitive impairment
Start: 2024-07-01Target: 150Updated: 2024-12-03
LONGITUDINAL STUDY OF THE POSITRON EMISSION TOMOGRAPHY (PET) TRACER FOR TAU 18F-PI-2620 IN INDIVIDUALS WITH DOWN SYNDROME
Not yet recruitingCTIS2024-515574-27-00
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant PauAlzheimer disease, Down Syndrome
Target: 80Updated: 2025-06-19
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RecruitingNCT07020026
Michael J. Fox Foundation for Parkinson's ResearchParkinson's Disease
Start: 2025-05-12End: 2027-06-30Target: 60Updated: 2025-06-13

Phase 3

[18F]PI-2620 Phase 3 Histopathological Study
RecruitingNCT05641688
Life Molecular Imaging LtdAlzheimer Disease
Start: 2022-12-01End: 2027-06-30Target: 200Updated: 2026-01-07